Cardiology (all articles) | Page 53 of 178 | Links Medicus Content Curation & Alerts in Medicine

Cohort Study: Mortality among patients with early-onset atrial fibrillation and rare variants in cardiomyopathy and arrhythmia genes.

25 May, 2022 | 10:52h | UTC

Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes – JAMA Cardiology

Commentaries:

Mortality in Early-Onset AF and Rare Variants in Cardiomyopathy and Arrhythmia Genes – American College of Cardiology

Disease-Associated Cardiomyopathy Variants May Increase Mortality Risk in Early-Onset AF – HCP Live

Commentary on Twitter

In early-onset atrial fibrillation (diagnosed before age 66), genetic testing revealed cardiomyopathy and arrhythmia rare variants were associated with a higher risk of death in long term follow up. https://t.co/a1C9w1tZm7 #atrialfibrillation #genetictesting

— JAMA Cardiology (@JAMACardio) May 13, 2022

The time-varying cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials.

25 May, 2022 | 10:37h | UTC

The Time-varying Cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials – Diabetes, Obesity & Metabolism

Commentary: Survival time analysis shows CV benefits of GLP1 receptor agonists – medwireNews

AHA Scientific Statement: Ambulatory blood pressure monitoring in children and adolescents.

24 May, 2022 | 10:47h | UTC

Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement From the American Heart Association – Hypertension

News Release: Statement updates ambulatory blood pressure classification in children and adolescents – American Heart Association

Long-term follow up of RCT: Effects of long-term metformin and lifestyle interventions on cardiovascular events in the Diabetes Prevention Program and Its Outcome Study (DPPOS).

24 May, 2022 | 10:39h | UTC

Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study – Circulation

News Release: Lifestyle changes, meds effective to prevent or delay Type 2 diabetes; no change in CVD – American Heart Association

Expert Analysis: Vascular toxicities of novel cancer therapies.

24 May, 2022 | 07:50h | UTC

Vascular Toxicities of Novel Cancer Therapies – American College of Cardiology

Review: Current and emerging classes of pharmacological agents for the management of hypertension.

24 May, 2022 | 07:47h | UTC

Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension – American Journal of Cardiovascular Drugs (if the link is paywalled, try this one)

Mechanical circulatory support: primer for nephrology consultants.

24 May, 2022 | 07:38h | UTC

Mechanical Circulatory Support: Primer for Consultant Specialists – Clinical Journal of the American Society of Nephrology

A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support: A State-of-the-Art Review – JACC: Heart Failure

2019 EACTS Expert Consensus on long-term mechanical circulatory support – European Journal of Cardio-Thoracic Surgery

Mechanical Circulatory Support Devices for Cardiogenic Shock: State of the Art – Critical Care

M-A: Effect of Sodium-Glucose Cotransporter 2 Inhibitors for heart failure with preserved ejection fraction.

24 May, 2022 | 07:33h | UTC

Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials – Frontiers in Cardiovascular Medicine

Expert Consensus: Treatment of coronary bifurcation lesions.

23 May, 2022 | 01:36h | UTC

– Treatment of coronary bifurcation lesions, part I: implanting the first stent in the provisional pathway. The 16th expert consensus document of the European Bifurcation Club – EuroIntervention

– Treatment of coronary bifurcation lesions, part II: implanting two stents. The 16th expert consensus document of the European Bifurcation Club

Commentary on Twitter

Coinciding with the beginning of #EuroPCR, the 16th Expert Consensus Document of the European Bifurcation Club is online ahead of print with two publications: Part 1 on the provisional pathway and Part 2 on two-stent strategies. https://t.co/cfECcOi0GJ https://t.co/gjUrYKV2qK pic.twitter.com/IlX8GhKLQU

— Davide Capodanno (@DFCapodanno) May 15, 2022

Cohort Study: Association of thyroid hormone treatment intensity with cardiovascular mortality.

23 May, 2022 | 01:23h | UTC

Association of Thyroid Hormone Treatment Intensity With Cardiovascular Mortality Among US Veterans – JAMA Network Open

Commentaries:

Thyroid Hormone Treatment Intensity and Cardiovascular Mortality – American College of Cardiology

Thyroid Hormone Treatment Intensity May Be Modifiable Risk Factor for CV Mortality – HCP Live

Commentary on Twitter

In this cohort study of US Veterans on thyroid hormone therapy, both exogenous hyperthyroidism and hypothyroidism contributed to the increased risk of cardiovascular mortality after adjusting for demographic and traditional cardiovascular risk factors. https://t.co/NO4776Ia4m

— JAMA Network Open (@JAMANetworkOpen) May 12, 2022

Definitions and standardized endpoints for treatment of coronary bifurcations.

23 May, 2022 | 01:18h | UTC

Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations – EuroIntervention

Commentary on Twitter

https://twitter.com/DFCapodanno/status/1526917363311968257

QRS micro-fragmentation as a mortality predictor.

23 May, 2022 | 01:19h | UTC

QRS micro-fragmentation as a mortality predictor – European Heart Journal

Editorial: The fractionated QRS complex for cardiovascular risk assessment – European Heart Journal

Commentary on Twitter

QRS micro-fragmentation as a mortality predictor: discover more in EHJ! https://t.co/P0gkPFpIs8 #EKG #QRS #fragmentation #prediction #outcome #cardiotwitter @escardio @ESC_Journals pic.twitter.com/8IAIL3fXFF

— EHJ Editor-in-Chief (@ehj_ed) February 22, 2022

Under a https://creativecommons.org/licenses/by/4.0/ license

Cohort Study: Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy.

23 May, 2022 | 00:45h | UTC

Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy – Journal of the American College of Cardiology

Commentary: Clinical Features and Course of Preadolescent Hypertrophic Cardiomyopathy – American College of Cardiology

Review: Allergic asthma is a risk factor for human cardiovascular diseases.

23 May, 2022 | 00:48h | UTC

Allergic asthma is a risk factor for human cardiovascular diseases – Nature Cardiovascular Research

Commentary on Twitter

A Review in @NatureCVR discusses how asthma and allied allergic conditions may contribute to the prevalence, incidence and progression of cardiovascular diseases and vice versa. https://t.co/6kRj9LvOfa pic.twitter.com/Ydq8X2k1rY

— Nature Portfolio (@NaturePortfolio) May 18, 2022

AHA Scientific Statement: Preventing and managing falls in adults with cardiovascular disease.

20 May, 2022 | 11:20h | UTC

Preventing and Managing Falls in Adults With Cardiovascular Disease: A Scientific Statement From the American Heart Association – Circulation: Cardiovascular Quality and Outcomes

News Release: Statement addresses ways to prevent heart-related risks for falling – American Heart Association

Commentary: AHA News: Falls Can Be a Serious, Poorly Understood Threat to People With Heart Disease – HealthDay

SCAI guidelines for the management of patent foramen Ovale.

20 May, 2022 | 11:01h | UTC

SCAI Guidelines for the Management of Patent Foramen Ovale – JSCAI

Editorial: New SCAI Guidelines: Trying to Close the Holes in the PFO Literature – JSCAI

Commentary: PFO Closure Guidelines Address Older Adults, Trial-Excluded Groups— Document acknowledges skimpy evidence – MedPage Today (free registration required)

Advances in the management of cardioembolic stroke associated with patent foramen ovale – The BMJ

Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology – Neurology

Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke – JAMA (link to abstract – $ for full-text)

Management of the Patient With Patent Foramen Ovale in 2021: A Spectrum of Cases – Mayo Clinic Proceedings

RCT: Apixaban is not superior to the standard of care (vitamin K antagonist or antiplatelet therapy if anticoagulation is indicated or not, respectively) after transcatheter aortic valve implantation.

20 May, 2022 | 10:59h | UTC

Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial – European Heart Journal (link to abstract – $ for full-text)

Editorial: Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS – European Heart Journal

Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism after TAVR: The ADAPT-TAVR Randomized Clinical Trial – Circulation

Comparing Single- and Dual-Antiplatelet Therapies After Transcatheter Aortic Valve Implantation – The Annals of Thoracic Surgery

Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient‐Level Meta‐Analysis – Journal of the American Heart Association

Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation – New England Journal of Medicine

Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Implantation for Aortic Stenosis – ATLANTIS – American College of Cardiology

M-A: Management of asymptomatic severe aortic stenosis.

20 May, 2022 | 10:54h | UTC

Management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis – openheart

Commentaries on Twitter

Management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis @justvick @vass_vassiliou @MarcDweck @jhfrudd https://t.co/eFJbT3AiPn pic.twitter.com/g2GwKvlODW

— Open Heart (@Open_HeartBMJ) May 18, 2022

Our latest work led by #WIC @justvick on earlier surgery in asymptomatic aortic stenosis @Open_HeartBMJ inc all RCT & observational studies – huge suggestion that ‘earlier the better!’ https://t.co/u56LffOjAD great collaboration with @MarcDweck @jhfrudd @HEARTinMagnet #epeeps pic.twitter.com/WlKn1e6c9S

— Vass Vassiliou (@vass_vassiliou) May 18, 2022

Perspective: The need for increased pragmatism in cardiovascular clinical trials.

19 May, 2022 | 10:48h | UTC

The need for increased pragmatism in cardiovascular clinical trials – Nature Reviews Cardiology (if the link is paywalled, try this one)

Commentary on Twitter

In our latest Review, @ShahzebKhanMD and colleagues discuss the need for increased pragmatism in #cardiovascular clinical trials: https://t.co/LUlrPKusAk pic.twitter.com/cxAYmD2nyS

— Nature Reviews Cardiology (@NatRevCardiol) May 17, 2022

Prescribing SGLT2 inhibitors in patients with chronic kidney disease: expanding indications and practical considerations.

19 May, 2022 | 10:43h | UTC

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations – Kidney International Reports

Commentary on Twitter

Prescribing #SGLT2 Inhibitors in Patients with #CKD : Expanding Indications and Practical Considerations

👍🏻 This interesting article discusses about practical considerations of #SGLT2i from #nephrology point of view https://t.co/Wq2plAqbhq @Nephro_Sparks @NephJC @kidney_boy pic.twitter.com/eHmpOHso86

— Henry Han (@HanCardiomd) May 17, 2022

Under a CC BY-NC-ND 4.0 license

Managing stage 1 hypertension: Consider the risks, stop the progression.

19 May, 2022 | 10:27h | UTC

Managing stage 1 hypertension: Consider the risks, stop the progression – Cleveland Clinic Journal of Medicine

RCT: Effect of transcatheter aortic valve implantation vs. surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis.

18 May, 2022 | 11:12h | UTC

Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment of Aortic Stenosis With Transcatheter Aortic Valve Implantation – JAMA (free for a limited period)

Commentary on Twitter

In this study, among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk, treatment with TAVI was noninferior to surgery with respect to all-cause mortality at 1 year. https://t.co/ORegyw1PKs

— JAMA (@JAMA_current) May 17, 2022